US20140154737A1 - Cross-linked poly-e-lysine particles - Google Patents

Cross-linked poly-e-lysine particles Download PDF

Info

Publication number
US20140154737A1
US20140154737A1 US14/112,731 US201214112731A US2014154737A1 US 20140154737 A1 US20140154737 A1 US 20140154737A1 US 201214112731 A US201214112731 A US 201214112731A US 2014154737 A1 US2014154737 A1 US 2014154737A1
Authority
US
United States
Prior art keywords
cross
polymer
lysine
poly
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US14/112,731
Other languages
English (en)
Inventor
Donald Wellings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spheritech Ltd
Original Assignee
Spheritech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spheritech Ltd filed Critical Spheritech Ltd
Assigned to SPHERITECH LTD reassignment SPHERITECH LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WELLINGS, Donald
Publication of US20140154737A1 publication Critical patent/US20140154737A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/126—Polymer particles coated by polymer, e.g. core shell structures
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D177/00—Coating compositions based on polyamides obtained by reactions forming a carboxylic amide link in the main chain; Coating compositions based on derivatives of such polymers
    • C09D177/04—Polyamides derived from alpha-amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/096—Polyesters; Polyamides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/098—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer formed in the presence of the enzymes or microbial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2477/00—Characterised by the use of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Derivatives of such polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/249921—Web or sheet containing structurally defined element or component
    • Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
    • Y10T428/249987—With nonvoid component of specified composition
    • Y10T428/249991—Synthetic resin or natural rubbers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y10T428/2998—Coated including synthetic resin or polymer

Definitions

  • This invention relates to a polymeric support, a method of preparing the support and the use of the support in a solid phase process.
  • the invention relates to a polymeric support comprising cross-linked poly- ⁇ -lysine.
  • the support is useful in a wide range of physical and chemical processes especially where interaction with a substrate is required for example solid phase synthesis, solid phase extraction, solid phase reagents, immobilization of species, cell culture, catalysis, chromatography and in medical diagnostics.
  • Poly- ⁇ -lysine is a naturally occurring short chain polydispersed polyamide consisting of the amino acid lysine linked through amide bonds between the carboxyl and the epsilon ( ⁇ ) amino group. This structure is unusual in that the amide bonds are formed between the carboxyl and ⁇ amino groups of lysine whereas a normal peptide bond between amino acids in a peptide and traditionally employed poly-lysine, is formed between the carboxyl and a amino groups.
  • the polydispersity in naturally occurring poly- ⁇ -lysine is typically between 25-35 amino acids. In traditional commercially available poly-lysine the peptide has a much broader poorly controlled polydispersity typically containing anything from 5-500 amino acids.
  • Cross-linked poly- ⁇ -lysine structurally has a more elastic nature than traditional poly-lysine due to the greater chain length between the amide bonds.
  • Structurally poly- ⁇ -lysine is effectively an ⁇ -amino Nylon 5.
  • Poly- ⁇ -lysine is currently manufactured by bacterial fermentation on a large scale as a food preservative. It is inexpensive and readily available in commercial quantities.
  • Solid support materials useful in solid phase synthetic processes are known.
  • a wide range of physical and chemical processes employ solid support materials including by way of example synthesis of organic molecules, in particular peptides and oligonucleotides, immobilization of species, support of catalysts, ion exchange, extraction of species from a material, diagnostics and chromatography.
  • multi-stage synthesis of an organic molecule involves numerous isolation steps to separate intermediates, produced at each stage, before progressing to the subsequent stage. These processes are often time-consuming, expensive and may be inefficient as regards yield.
  • the intermediates often require purification to remove excess reagents and reaction by-products and procedures such as precipitation, filtration, bi-phase solvent extraction; solid phase extraction, crystallization and chromatography may be employed.
  • Solid phase synthesis offers some advantages over solution phase synthesis. For example, isolation procedures used in solution phase synthesis may to some extent be avoided by reversibly attaching the target molecule to a solid support. Excess reagents and some of the side-products may be removed by filtration and washing of the solid support. The target molecule may be recovered in essentially quantitative yield in some processes which is typically particularly difficult in solution phase synthesis. In addition, the time required to perform operations on a solid support is typically much less than that required carrying out the equivalent stage in a solution phase synthesis.
  • Immobilization of species in a range of processes is also known.
  • polymer supports are commonly used for the immobilization of catalysts for use in traditional organic chemistry including chemo and bio catalysis.
  • Immobilized enzymes may be employed to perform organic chemical reactions or for chiral resolution, for example the use of immobilized Penicillin amidase for the resolution of secondary alcohols (E. Baldaro et al. Tet. Asym. 4, 1031, (1993) and immobilized Penicillin G amidase is also used for the hydrolysis of Benzylpenicillin in the manufacture of Amoxicillin (Carleysmith, S. W. and Lilly, M.D. Biotechnol. Bioeng., 21, 1057-73, 1979).
  • Solid supports are also used to immobilize biological macromolecules for medical and diagnostic applications. This includes immobilization of proteins, monoclonal and polyclonal antibodies. Cell culture is commonly carried out on solid supports with specific surface characteristics and morphology. Immobilized enzymes on the supports can also be employed as sensors to generate a signal.
  • An example is the detection of glucose by the glucose oxidase/peroxidase coupled enzyme system, in which the presence of glucose generates hydrogen peroxide which in turn is the substrate for peroxidase for the oxidation of a wide variety of substrates to provide a coloured, fluorescent or luminescent signal.
  • a variety of fluors whose fluorescence is sensitive to specific cations or anions may be utilized to indicate concentrations of specific ions including hydrogen ions for pH measurement.
  • Polymeric particles are often used in chromatography where the solid supports are termed stationary phases.
  • the cost of stationary phases may be restrictive.
  • the physical nature of the stationary phase can reduce the effectiveness of the technology.
  • the soft polymers often used for affinity, ion-exchange and gel permeation chromatography cannot be used at high flow rates because of the deformable nature of the particles.
  • the rigid macroporous polymers used for many other modes of chromatography can often be mechanically friable and subsequently suffer from a short lifetime.
  • Solid phase supports generally comprise polymer particles of a particular size and physical nature to suit the application. For ease of use these polymer particles are often spherical and have a defined particle size distribution. The spherical nature of the particles improves the flow and filtration characteristics of the polymer. Although the uses of solid supports have operational advantages there are disadvantages to the solid phase approach.
  • polystyrene In peptide synthesis, polystyrene is widely employed as a polymer support for supporting the growing peptide and is relatively low-cost, widely available and provides acceptable performance in peptide synthesis.
  • Other commercially available supports commonly used for solid phase synthesis of peptides and oligonucleotides may be expensive, for example due to the complex manufacturing processes.
  • Microporous polymers and macroporous polymers are generally used. Microporous polymers have a relatively low level of cross-linker which allows the polymer particles to solvate and consequently swell in suitable solvents.
  • Macroporous polymers often have a high level of cross-linker in the polymer matrix and contain large pores. These polymer particles are generally rigid and have good flow characteristics and are suitable for use in packed columns.
  • a cross-linked poly- ⁇ -lysine polymer provides an excellent combination of characteristics, may be tailored according to the desired properties by appropriate selection of the cross-linker and may be employed in a wide-range of applications cost-effectively.
  • the invention provides a cross-linked poly- ⁇ -lysine polymer.
  • the cross-linked poly- ⁇ -lysine polymer is particularly useful in providing a support for a wide-range of applications especially where the cross-linking provides a polymer which is insoluble in water and other solvents. Where lower levels of cross-linking are employed, the polymer may be soluble in water and this provides advantage in certain applications as described below.
  • the polymer comprises poly- ⁇ -lysine and a cross linker linked by amide bonds.
  • the polymer may be in any suitable form including a non-particulate macro form for example a sheet, article, fibre, or in particulate form.
  • the poly- ⁇ -lysine component of the cross-linked poly- ⁇ -lysine is the principle component of the cross-linked polymer.
  • the cross-linker acts to bond poly- ⁇ -lysine polymers together such that the poly- ⁇ -lysine polymers provide a structure, for example a lattice for use in a range of applications including support for synthesis of organic molecules, for example polypeptides and polynucleotides, chromatography, use as a support for functional materials as described herein below.
  • the poly- ⁇ -lysine polymer is suitably cross-linked by reacting a cross-linker having at least two functional groups, preferably two or more carboxylic acid groups, able to react with the free alpha ( ⁇ ) amino groups in the poly- ⁇ -lysine polymer.
  • the cross-linker may have three or more functional groups to link to the same number of poly- ⁇ -lysine polymer chains or fewer chains but with multiple links to one or more such chains.
  • the cross-linker may contain other functional groups which do not participate in the cross-linking reaction and remain available for reaction with other species during use of the cross-linked polymer.
  • the level of cross-linking in the polymeric support can be used to control the physical form and chemical reactivity of the final cross-linked poly- ⁇ -lysine.
  • Introduction of high levels of cross-linking will produce rigid structures suitable for the preparation of macroporous polymer supports, whereas a low level of cross-linking will produce softer more microporous materials.
  • the amine functionality is high with low levels of cross-linking, which can be readily tailored by controlled capping.
  • the handling, solvation and physical properties can also be defined by the type of cross-linker introduced.
  • the cross-linker comprises a specific compound or group of compounds.
  • the cross-linker may comprise a repeat unit and be polydisperse however, the polydispersity is narrow to ensure appropriate control over the lattice structure formed upon cross-linking.
  • the crosslinker comprises at least two functional groups capable of reacting with an alpha carbon amine of poly- ⁇ -lysine. Examples of common functional groups suitable for this purpose include carboxylic acids.
  • Amide bonds are biodegradable and the cross-linked polymer of the invention and supports comprising it are especially useful in applications in which biodegradability is important. Further, amide bonds may be metabolized for example by enzymes including proteases, as well as being biodegradable and are particularly advantageous for use in medical applications and especially medical use on or in the human or animal body.
  • the polymers and supports of the invention provide benefit in medical applications where the polymer or support suitably degrades over time thereby avoiding the need for procedures to remove the support after its function has been completed.
  • the bonds between the cross-linker and the poly- ⁇ -lysine comprise amide bonds, preferably at least 1% of the epsilon amine groups are cross-linked, more preferably at least 50%, desirably at least 90% and especially substantially all of the bonds are amide bonds.
  • the polymer is lightly cross-linked and from 1 to up to 50%, 1 to 20% and 1 to 10% of the epsilon amine groups are cross-linked.
  • Lightly cross-linked polymers and supports of the invention are especially useful in synthesis of organic species, for example peptides and nucleotide sequences, and in delivery of active species, for example pharmaceutically active agents.
  • the cross-linker comprises two or more carboxylic acid groups and an aliphatic chain linking the two or more groups.
  • the cross-linker may comprise a polyacid.
  • the cross-linker comprises a compound of formula X[CO 2 H] n where n is 2 or more, preferably 2 to 6 more preferably 2 to 4 and X is a hydrophobic or hydrophilic linking group, preferably aliphatic.
  • group X has a molecular weight of 14 to 250, more preferably 28 to 140 excluding any functional substituents on the linking group.
  • X may contain heteroatoms for example oxygen and nitrogen as part of the backbone of the linking group and may contain functional groups for reaction with other species during use of the cross-linked poly- ⁇ -lysine polymer.
  • the aliphatic chain linking the acid groups may be hydrophilic, preferably a bis-carboxy-polyalkylene glycol, for example bis-carboxy-polyethyleneglycol, or the aliphatic chain may be hydrophobic providing a hydrophobic cross-linker, for example, sebacic acid provides a more lipophilic support.
  • the cross-linker may be derived from a precursor material, for example an anhydride. Examples of other suitable cross-linkers include nitrilotriacetic acid, glutaric acid and HOOCCH 2 CH 2 CONHCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 NHCO CH 2 CH 2 COOH.
  • the cross linker is selected according to its solvation characteristics such that upon reaction with the poly- ⁇ -lysine polymer, the polymer and cross-linker are contained within a disperse phase comprising a solvent for the cross-linker and poly- ⁇ -lysine within an immiscible continuous phase.
  • X comprises a hydrocarbon group and comprises only hydrogen and carbon atoms, preferably 2 to 14, more preferably 3 to 12 and especially 5 to 8 carbon atoms.
  • the hydrocarbon group may be linear or branched, preferably linear.
  • the hydrocarbon group may be saturated or unsaturated, preferably saturated.
  • Examples of preferred cross-linkers include di-carboxylic acids having 8 to 12 carbon atoms such as sebacic acid, dodecanedioic acid and azelaic acid.
  • the poly- ⁇ -lysine may be derivatised or modified prior to cross-linking to allow other cross-linking chemistry familiar to those skilled in the art.
  • the poly- ⁇ -lysine may be cross-linked using an amino acid for example aspartic acid and glutamic acid.
  • the cross-linked poly- ⁇ -lysine in this case would only generate naturally occurring amino acids only upon degradation. Reaction with cystine for example would produce a polymer cross-linked in a similar way but in this instance the structure would contain a cysteine disulfide bridge, which again on degradation would generate naturally occurring amino acids.
  • cross-linkers examples include glutamic acid, cystine, EDTA (ethyenediaminetetraacetic acid), adipic acid, dodecanedioic acid, synthetic peptides especially peptides based upon the structure of natural collagen, synthetic peptides containing the tripeptide sequence -Arg-Gly-Asp-, the cell binding peptide in fibrinogen and other natural proteins, naturally occurring polymers that contain multiple carboxylic acid groups including gelatin, alginic acid and crown ethers with multiple carboxylic acids especially suitable for use in metal chelation and chromatography. Further suitable examples are shown below:
  • the polydispersity of the poly- ⁇ -lysine is not critical, in a preferred embodiment the polydispersity of the poly- ⁇ -lysine is suitably from 10 to 50 and preferably between 25-35 amino acids. A narrower polydispersity allows for more precise control over the ultimate properties of the cross-linked polymer support.
  • Cross-linked poly- ⁇ -lysine will have many applications for example in several modes of chromatography but may be of particular advantage for chiral separations due to the repeating L-chiral centers along the chain.
  • the pendant a amino groups can be readily modified to incorporate other chromatographic binding sites or other chiral moieties that will impart a range of chiral selective properties on the support.
  • the relative amount of poly- ⁇ -lysine and cross-linker are selected such that the poly- ⁇ -lysine is the principle component of the cross-linked poly- ⁇ -lysine polymer.
  • the relative amounts of poly- ⁇ -lysine polymer and cross linker will be selected to provide stoichiometric molar equivalents as regards the alpha amine groups of the poly- ⁇ -lysine and the cross-linking functional groups.
  • amine functionality is desired, a corresponding lower amount of cross-linker is employed to provide the desired proportion of free amine groups.
  • the cross-linked poly- ⁇ -lysine polymer has from 0 to 95% of its alpha amine groups as free amine groups.
  • the cross-linked poly- ⁇ -lysine polymer will suitably exhibit relatively rigid characteristics.
  • the polymer is suitably relatively soft or gel-like. Soft or gel-like polymers are especially useful in the synthesis of polypeptides, particularly long polypeptides.
  • the cross-linked poly- ⁇ -lysine polymer comprises from greater than 0.001 to 20 mmol/g, 0.01 to 10 mmol/g of cross-linked poly- ⁇ -lysine polymer, and preferably from 0.1 to 8 mmol/g for example from 1 to 8 mmol/g especially for polypeptide synthesis.
  • the cross-linked poly- ⁇ -lysine polymer comprises from 0.01 to 0.3 mmol/g, particularly advantageous for the synthesis of nucleic acid sequences.
  • the cross-linker and poly- ⁇ -lysine polymer are reacted in a solvent in which they are solvated for example water, which is dispersed within an immiscible continuous phase, for example dichloromethane.
  • concentration of the reactants in the solvent will affect the degree to which the cross-linked polymer shrinks on removal of the solvent and provides larger pores within the cross-linked polymer.
  • Dimethylformamide may be employed as the solvent.
  • the invention provides a particulate support comprising a cross-linked poly- ⁇ -lysine polymer according to the invention.
  • Polymeric particles may typically be made by a dispersion or emulsion polymerization process in which a solution of monomers is dispersed in an immiscible solvent (continuous phase) prior to initiation of the polymerization.
  • the polymer particles formed are typically then filtered, washed and classified to isolate the required particle size distribution.
  • the cross-linked polymer is formed on or around a particle, preferably a hollow particle. This provides a seeding effect and allows polymer particles of a narrow particle size distribution to be formed.
  • the cross-linked polymer is formed on the surface of a particle.
  • the particle is silica but may be another known polymer for example polystyrene and hydroxyl apatite.
  • a coated silica particle is suitable for applications in high pressure liquid chromatography for example.
  • the cross-linked polymer is formed on or around nanoparticles. This provides a seeding effect and allows polymer particles of nanoparticle size to be formed. Such particles will have healthcare applications in drug delivery such as transfection for example.
  • the cross-linked poly- ⁇ -lysine polymer may be reacted further to provide particular functionality for a given application.
  • the polymer is reacted with a compound having at least three functional groups, two for reacting with the polymer to provide cross-linking between two polymer chains and the other to provide free functionality for use in the desired application.
  • the cross-linked poly- ⁇ -lysine support may be further functionalised, for example by conversion to a carboxylic acid using succinic acid as desired.
  • an amine functionalised support may be treated with N-hydroxysuccinimide and 1-Ethyl-3-[3-dimethylaminopropyl]carbodimide hydrochloride in preparation of an activated polymer for immobilising a protein, for example protein A.
  • the cross-linked polymer preferably a particulate cross-linked polymer may also comprise a functional material supported by the polymer.
  • suitable functional materials include a catalyst, an initiator species for peptide synthesis, a pharmaceutical active, an agrochemical active, a macromolecule, an enzyme, a nucleic acid sequence and a protein.
  • the cross-linked polymer is supported on a hollow particle.
  • the cross-linked polymer may form a lattice or net around whole or part of the particle.
  • the hollow particle suitably comprises functional groups, for example carboxylic acid groups which may react with free amine groups on the polymer and provide a covalent link between the cross-linked polymer and the particle.
  • the cross-linked poly- ⁇ -lysine polymer or particulate support comprising the polymer invention is particularly useful in supporting precious metal catalysts, for example palladium catalysts.
  • precious metal catalysts for example palladium catalysts.
  • a particularly advantageous example is palladium acetate supported on cross-linked poly- ⁇ -lysine functionalized to form a carboxylic acid.
  • the invention provides in a further aspect a method for producing a particulate support material comprising the steps of providing a particle, preferably a hollow particle, contacting the particle with a solution of poly- ⁇ -lysine and cross-linker, effecting polymerisation of the poly- ⁇ -lysine and cross-linker so as to form a polymer coating on the surface of the particle.
  • the polymerisation is initiated by a polymerisation initiation process known to those skilled in the art.
  • hollow particles mixed with a solution of poly- ⁇ -lysine and carboxyl functional cross-linker are added to a solvent which is immiscible with the poly- ⁇ -lysine and cross-linker solvent and a carbodimide added to effect polymerisation.
  • the solvent is for example toluene.
  • the polymer coating may be covalently linked to the particle either during the polymerization or subsequent to the polymerization.
  • one or more of the poly- ⁇ -lysine and cross-linker can be covalently linked to the particle surface prior to initiation of the polymerization.
  • the particle is hollow.
  • the particulate support of the invention may be used in any chemical or physical process in which a solid support is used.
  • the support may be employed in applications involving electro-conducting and light emitting polymers.
  • the support containing light emitting polymers may be arranged on display panels.
  • the particulate support is particularly useful for solid phase synthesis of an organic species, particularly macromolecules.
  • the particulate support may be employed in the synthesis of peptides, oligonucleotides or oligosaccharides.
  • the invention further provides for the use of a particulate support according to the invention as a solid phase in a chromatography process.
  • the particulate support of the invention is also useful for solid phase extraction to remove species from a liquor which is contacted with the support, whether in batch form or as a flow over the support, for example ion extraction and ion exchange.
  • the support of the invention may be used to immobilize species including antibodies, oligonucleotides, enzymes or fluors and may be positioned in an array, with each support assaying a different component of a solution. Particles having ligands covalently attached to their surface, or via polymers bound to the surface may be employed as ‘wells’. Specific binding of a target ligand such as antigen or complimentary DNA or RNA sequence may then be detected using established methods.
  • a target ligand such as antigen or complimentary DNA or RNA sequence
  • the particulate support of the invention also may be employed to immobilize a biocatalyst or whole cells for use in biocatalysis.
  • Biocatalysts are often used in columns or in systems with filter plates for separation of the solid phase from the mixture under extraction.
  • the particulate support of the invention is especially useful in immobilizing species including solid phase reagents, metal and other catalysts, bio-catalysts, enzymes, proteins, antibodies including polyclonal and monoclonal antibodies, whole cells and polymers.
  • the invention is particularly advantageous in supporting enzymes, for example the lipase Cal B. Lipase Cal B may be employed in a transesterification process.
  • the invention further provides for a method of enzymatic manufacture of biodiesel using a support of the invention.
  • the present invention is also especially useful in the immobilisation of affinity ligands such as Protein A.
  • Protein A is suitably used in the purification of monoclonal antibodies.
  • the particulate support of the invention may also be used in chemocatalysis, for example by immobilizing transition metal catalysts and ligands.
  • the present invention may be used in cell culture.
  • Mass culture of animal cell lines is fundamental to the manufacture of viral vaccines and many products of biotechnology.
  • Biological products produced by recombinant DNA technology in animal cell cultures include enzymes, synthetic hormones, immunobiologicals (monoclonal antibodies, interleukins, lymphokines) and anticancer agents.
  • Many simpler proteins can be produced using rDNA in bacterial cultures; more complex proteins that are glycosylated (carbohydrate-modified) currently must be made in animal cells.
  • An important example of such a complex protein is the hormone erythropoietin.
  • the cost of growing mammalian cell cultures is high, so companies are constantly looking to improve techniques.
  • Cells can be grown in suspension or as adherent cultures. However, adherent cells require a surface, which may be coated with extracellular matrix components to increase adhesion properties and provide other signals needed for growth and differentiation. Generally cells derived from solid tissues are adherent. Organotypic culture involves growing cells in a three-dimensional environment as opposed to two-dimensional culture dishes. This 3D culture system is biochemically and physiologically more similar to in vivo tissue, but is technically challenging to maintain because of many factors (e.g. diffusion). Gelatin is hydrolyzed collagen where inter and intra chain amide bonds have been hydrolyzed chemically to form soluble peptide chains. Collagen is an ideal and natural environment for cells to adhere and differentiate. The poly- ⁇ -lysine may also be co-polymerized with other proteins, for example gelatin to form a collagen like environment.
  • the invention provides for the use of a particulate, macroporous or microporous support or coating according to the invention to culture cells preferably on the surface of the support or coating.
  • stem cells may be cultured on the particulate support of the invention to reduce uncontrolled differentiation and to control desired differentiation.
  • the invention is beneficial for use in wound care.
  • Chronic wounds are exacerbated by metallino-proteases which can be rendered inactive by polymer particles that chelate metal ions required by the enzyme.
  • the cross-linked poly- ⁇ -lysine preferably capped with metal chelating species are suitable for use in this application.
  • the invention provides for the use of cross-linked poly- ⁇ -lysine or a particulate support comprising cross-linked poly- ⁇ -lysine as a wound treatment product or component thereof.
  • the wound treatment product may comprise a flexible article but preferably comprises a self-supporting article.
  • the wound treatment product suitably comprises a polymer or particulate support according to the invention and a component or a composition for treating a wound and/or a therapeutic agent.
  • the particulate support of the invention is also suitable for such uses unless otherwise stated.
  • the invention is particular useful in medical diagnostic tests such as immunoassay. Accordingly the invention further provides medical diagnostics for detecting the presence of a compound comprising a polymer according to the invention and a functional material such as an enzyme, for example horseradish peroxidase, supported by the polymer in the support for selectively reacting with or binding to the compound to be detected.
  • a functional material such as an enzyme, for example horseradish peroxidase
  • the polymer support of the present invention may be used in a medical diagnostic procedure where physical separation of the solid phase through a liquid phase.
  • the polymer support may be used as an absorbent.
  • the polymer support may be used to absorb household spillages, for example tea, coffee and wine, or may be used in larger-scale applications for example, to absorb oil from spillages.
  • the absorbent support may be used to absorb the spillage and then left to biodegrade or, in the case of oil spillage in a body of water, effectively trap the oil and retain the oil in a buoyant mass for collection and disposal.
  • the cross-linked poly- ⁇ -lysine is biodegradable facilitating disposal with reduced environmental impact.
  • the polymer support of the invention may be used as a biodegradable carrier to carry a compound which is to be released over a period of time, for example a pharmaceutical or agrochemical compound or composition.
  • a compound which is to be released over a period of time for example a pharmaceutical or agrochemical compound or composition.
  • This use provides a means of tailoring a dosage regime of the compound according to the loading of the compound in the support.
  • this may be advantageous in assisting the correct dosage of an active, for example with continuous slow release rather than requiring a patient to take periodic large doses, for example in chemotherapy.
  • FIG. 1 shows a diagrammatic representation of poly- ⁇ -lysine.
  • FIG. 2 shows a diagrammatic representation of poly- ⁇ -lysine cross-linked with a bifunctional carboxylic acid.
  • FIG. 3 shows a diagrammatic representation of poly- ⁇ -lysine cross-linked with aspartic acid as example.
  • FIG. 4 shows a diagrammatic representation of poly- ⁇ -lysine cross-linked with cystine.
  • FIG. 5 shows a diagrammatic representation of poly- ⁇ -lysine cross-linked with nitrilotriacetic acid.
  • FIGS. 6 a and 6 b show photographs of the Pd 2+ and Pd 0 chelated microspheres.
  • FIG. 7 shows a microscope photograph of the particles.
  • FIG. 8 shows an HPLC test chromatogram
  • Hollow polymer particles 500 cm 3 , Akzo Nobel—Expancel, grade 920 DEX80 were placed in a 1 dm 3 Polypropylene bottle and covered with sodium hydroxide solution (100 g in 500 cm 3 4:1v/v water/methanol). The mixture was left on a roller at room temperature overnight.
  • the particles were washed in a separating funnel with water (5 ⁇ 500 cm 3 ), aqueous hydrochloric acid (1 mol/dm 3 , 5 ⁇ 500 cm 3 ) then water (5 ⁇ 500 cm 3 ). The particles were then washed with methanol (5 ⁇ 500 cm 3 ) and air dried. Particles having free carboxylic acid groups on the surface of the [particle were created.
  • DEX80 particles prepared above were placed in a round bottomed flask and suspended in a solution (100 cm 3 ) of poly- ⁇ -lysine (10 g, 51.5 mmol of —NH 2 ), nitrilotriacetic acid (2.64 g, 41.5 mmol COOH) and N-methylmorpholine (4.2 g, 41.5 mmol).
  • This slurry was dispersed with rapid stirring in dichloromethane (DCM) (250 cm 3 ) containing SPAN 80 (2% w/v).
  • DCM dichloromethane
  • the DCM layer was removed by decantation and the particles were washed on a 75 ⁇ m stainless steel sieve with copious amounts of tap water. The particles were transferred to a glass sinter and washed with water (5 ⁇ 500 cm 3 ) then washed with methanol (5 ⁇ 500 cm 3 ) and air dried (yield 5.8 g).
  • the amine loading of the cross-linked poly- ⁇ -lysine was determined by coupling Fmoc-Gly-OH to the polymer followed by Fmoc assay. The loading was 0.9 mmol/g (theoretical maximum 1 mmol/g).
  • DEX80 particles prepared above were placed in a round bottomed flask and suspended in a solution (100 cm 3 ) of poly- ⁇ -lysine (10 g, 51.5 mmol of —NH 2 ), HOOCCH 2 CH 2 CONHCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 NHCO CH 2 CH 2 COOH (4.99 g, 26.7 mmol COOH) and N-methylmorpholine (2.7 g, 26.7 mmol).
  • This slurry was dispersed with rapid stirring in toluene (250 cm 3 ) containing SPAN 80 (5% w/v).
  • a solution of EDCI (10 g, 52 mmol) in DCM (250 cm 3 ) was added and the polymerisation allowed to proceed for 1.5 h.
  • the organic layer was removed by decantation and the particles were washed on a 75 ⁇ m stainless steel sieve with acetone ( ⁇ 1 dm 3 ) and copious amounts of tap water.
  • the particles were transferred to a glass sinter and washed with water (5 ⁇ 500 cm 3 ) then washed with methanol (5 ⁇ 500 cm 3 ) and air dried (yield 11.5 g, ⁇ 90% of theory).
  • the amine loading of the cross-linked poly- ⁇ -lysine was determined by coupling Fmoc-Gly-OH to the polymer followed by Fmoc assay. The loading was 0.84 mmol/g (theory 1.7 mmol/g).
  • HMPA 4-Hydroxymethylphenoxyacetic acid
  • the coupling reaction was complete by Ninhydrin assay within 90 min.
  • the polymer support was washed on a glass sinter with aliquots of DMF (10 ⁇ 10 cm 3 ).
  • Fmoc-Gly-OH (0.89 g, 3 mmol) was coupled to the HMPA-polymer prepared above using DIC (0.5 g, 4 mmol) and DMAP (12 mg, 0.1 mmol) in N,N-dimethylformamide (DMF) (10 cm 3 ) for 60 min.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added and the reaction was allowed to stand for 3 minutes.
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ).
  • the coupling reaction was coupled to completion as determined by Ninhydrin assay.
  • the polymer support was washed with aliquots (10 ⁇ 10 cm 3 ) of DMF.
  • Piperidine/DMF (20 cm 3 , 20% v/v) was added to the mixture. The reaction was allowed to stand for 3 minutes. A second treatment with Piperidine/DMF (20 cm 3 , 20% v/v) for 7 minutes was carried out and the polymer support washed with DMF (10 ⁇ 10 cm 3 ) and diethyl ether (5 ⁇ 10 cm 3 ) before air drying (yield 1.93 g, 86% of theory).
  • Trifluoroacetic acid (TFA) (20 cm 3 ) containing water (2.5% v/v) and triisopropylsilane (TIPS) (2.5% v/v) was added to the peptide-HMPA-polymer prepared above (0.93 g). The mixture was left to cleave for 2 hours.
  • the polymer support was washed with TFA (5 ⁇ 15 cm 3 ) in a separating funnel.
  • TFA 5 ⁇ 15 cm 3
  • the combined TFA cleavage solutions and washes were reduced to an oil on a rotary evaporator.
  • the oil was triturated with diethyl ether to form a white solid.
  • the ether removed by decantation and the peptide air dried overnight (yield 0.4 g).
  • the peptide was shown to contain one major component by reversed phase HPLC and co-eluted with a sample of ACP(64-75) prepared on a traditional polymer support.
  • the peptide prepared on this cross-linked poly- ⁇ -lysine was a slightly higher quality compared to the ACP(64-75) prepared on the traditional polymer support.
  • Example 2 The procedure of Example 2 was repeated using the cross-linked polymer. Preparation of the ACP(64-75) as described above in Example 2 on the cross-linked poly- ⁇ -lysine prepared in Example 1.3 produced a peptide of similar quality even when all couplings were limited to 1 hour.
  • a cross-linked poly- ⁇ -lysine with 0.1 mmol/g amine loading (0.2 g) was treated with glutaric anhydride (2 g) in water (5 cm 3 ) overnight (resultant polymer was ninhydrin negative).
  • the polymer support was washed on a glass sinter with water (5 ⁇ 10 cm 3 ).
  • Morpholinoethane sulfonic acid (MES) buffer (25 mmol/dm 3 , pH 5.0, 3 ⁇ 20 cm 3 ) was used to wash the polymer support prior to protein coupling.
  • N-hydroxysuccinimide (1 g) was dissolved in cold MES buffer (25 mmol/dm 3 , pH 5.0, 2.5 cm 3 ) and this solution added to the polymer support.
  • EDCI (1 g) was dissolved in MES buffer (25 mmol/dm 3 , pH 5.0, 2.5 cm 3 ) and this solution added to the mixture.
  • the polymer support was mixed for 30 minutes on a bottle roller to activate.
  • the polymer support was washed with MES buffer (25 mmol/dm 3 , pH 5.0, 5 ⁇ 10 cm 3 ) and immediately, a solution of rProtein A (5 cm 3 , 4 mg/cm 3 in 25 mmol/dm 3 MES, pH 5.0) was added to the mixture and coupling allowed to proceed over a weekend at room temperature with mixing on a bottle roller.
  • the polymer support was drained on a glass sinter and washed with Trizma-HCl (30 cm 3 pH 7.4) to block any remaining N-hydroxysuccinimide esters on the polymer.
  • the polymer support was washed with water (10 ⁇ 10 cm 3 ) and stored as a slurry in water.
  • the Protein A based media was tested to determine whether it retained Human IgG using a packed chromatography column under standard conditions known to those skilled in the art using Human IgG. The column was shown to retain Human IgG as expected.
  • EDCI 36 g, 187.5 mmol
  • DCM 250 cm 3
  • the polymerisation was allowed to proceed for 90 minutes.
  • the DCM was removed by filtration and the polymer microspheres washed with DCM (3 ⁇ 500 cm 3 ) to remove residual Span 80.
  • the polymer was then washed thoroughly with water, neutralised with NaOH solution (1 mol/dm 3 ) then washed again with water followed by MeOH (3 ⁇ 500 cm 3 ), DCM (3 ⁇ 500 cm 3 ) then Et 2 O (2 ⁇ 250 cm 3 ).
  • the polymer microspheres were air dried overnight (yield 34 g).
  • Example 5 A sample of the polymer microspheres (2 g) prepared in Example 5 was measured into a polypropylene bottle. Glutaric anhydride (6 g) was dissolved in a solution of methanol (20 cm 3 ) and N-methylmorpholine (6 cm 3 ), added to the polymer and placed on the roller machine for 24 h.
  • a BCA assay was carried out using a Pierce® BCA assay kit (No. 23225) to determine the Cal B loading on the polymer. The loading was determined to be 218 mg Cal B per g of polymer.
  • the activity of the immobilized enzyme was shown to be equivalent to the free enzyme in solution confirming that the immobilized enzyme could be used in transesterification reactions including for example, the enzymatic production of biodiesel.
  • NTA Nitrilotriacetic Acid
  • Poly- ⁇ -lysine 40 g, 206 mmol amine content
  • NTA 10.96 g, 172 mmol carboxyl content
  • N-methylmorpholine 17.37 g, 172 mmol
  • DCM dichloromethane
  • EDCl (49.5 g, 258 mmol) was dissolved in DCM (400 cm 3 ) and added to the above dispersion. The polymerisation was allowed to proceed for 90 minutes. The DCM was removed by filtration and the polymer microspheres washed with DCM (3 ⁇ 500 cm 3 ) to remove residual Span 80. The polymer was then washed thoroughly with water, neutralised with NaOH solution (1 mol/dm 3 ) then washed again with water followed by MeOH (3 ⁇ 500 cm 3 ), DCM (3 ⁇ 500 cm 3 ) then Et 2 O (2 ⁇ 250 cm 3 ). The polymer microspheres were air dried overnight (yield 47 g).
  • a portion of the polymer microspheres (10 g, 10 mmol) prepared in Example 7 above was swollen in water in a polypropylene bottle.
  • a solution of EDCI (19.17 g, 100 mmol) and NTA (19.1 g, 100 mmol) in water ( ⁇ 100 cm 3 ) was prepared and added to the swollen microspheres. The mixture was left on a roller mill overnight to complete the capping with NTA.
  • This IMAC polymer was confirmed to be suitable for His-tagged protein purification by techniques known to those skilled in the art.
  • EDCI 36 g, 187.5 mmol
  • DCM 250 cm 3
  • the polymerisation was allowed to proceed for 90 minutes.
  • the DCM was removed by filtration and the polymer microspheres washed with DCM (3 ⁇ 500 cm 3 ) to remove residual Span 80.
  • the polymer was then washed thoroughly with water, neutralised with NaOH solution (1 mol/dm 3 ) then washed again with water followed by MeOH (3 ⁇ 500 cm 3 ), DCM (3 ⁇ 500 cm 3 ) then Et 2 O (2 ⁇ 250 cm 3 ).
  • the polymer microspheres were air dried overnight (yield 27 g).
  • a portion of the polymer microspheres (10 g, 10 mmol) prepared in Example 9 above was swollen in water in a polypropylene bottle.
  • a solution of EDCI (19.17 g, 100 mmol) and EDTA (29.2 g, 100 mmol) in water ( ⁇ 100 cm3) was prepared and added to the swollen microspheres. The mixture was left on a roller mill overnight to complete the capping with EDTA.
  • FIGS. 6 a and 6 b Photographs of the Pd 2+ and Pd 0 chelated microspheres are shown in FIGS. 6 a and 6 b.
  • DEX80 hollow particles 50 cm 3 were placed in a round bottomed flask and suspended in a solution (100 cm 3 ) of poly- ⁇ -lysine (10 g, 51.5 mmol of —NH 2 ), sebacic acid (2.6 g, 25.75 mmol COOH) and N-methylmorpholine (2.6 g, 25.75 mmol).
  • Superparamagnetic iron oxide nanoparticles (1 g, 50 nm particle size) were added and the slurry was dispersed with rapid stirring in dichloromethane (DCM) (250 cm 3 ) containing SPAN 80 (2% w/v).
  • DCM dichloromethane
  • SPAN 80 2% w/v
  • the DCM layer was removed by filtration and the particles were washed on a 500 ⁇ m stainless steel sieve with copious amounts of tap water. The particles were transferred to a glass sinter and washed with water (5 ⁇ 500 cm 3 ) and stored as a slurry in water.
  • FIG. 7 A microscope photograph of the particles is shown in FIG. 7 .
  • Superparamagnetic iron oxide nanoparticles (3 g, 50 nm particle size) were transferred to a thick walled glass tube. A saturated solution of citric acid in water was added and the mixture sonicated for 30 minutes at 40° C. The nanoparticles were washed with water (10 ⁇ 30 cm 3 ) using the magnetic properties to retain the particles during decantation.
  • Poly- ⁇ -lysine (2 g) was dissolved in water (5 cm 3 ) and added to the citric acid chelated nanoparticles. The mixture sonicated for 30 minutes at room temperature then EDCI (2 g) dissolved in water (2 cm 3 ) was added. The mixture sonicated for a further 30 minutes at 40° C. then left at room temperature overnight.
  • the nanoparticles were washed with water (10 ⁇ 30 cm 3 ), MeOH (5 ⁇ 30 cm 3 ) and Et 2 O (10 cm 3 ) using the magnetic properties to retain the particles during decantation.
  • the nanoparticles were air dried (yield 3.9 g).
  • the resultant citric acid cross-linked, poly- ⁇ -lysine coated nanoparticles were ninhydrin positive confirming the presence of amine coating.
  • the amine content of the nanoparticles was determined by coupling Fmoc-Leu-OH to the polymer followed by determination of the Fmoc content.
  • the amine loading was determined to be 66 ⁇ mol/g.
  • Silica particles (10 g, Kromasil, 10 ⁇ m, 1000 ⁇ pore) were suspended in a solution of aminopropyltrimethoxysilane in MeOH/water (50 cm 3 , 1% w/v, 10% water), mixed for 5-10 minutes then washed with MeOH and DMF before transferring to a polypropylene bottle. DMF (50 cm 3 ) was added followed by glutaric anhydride (5 g) and N-methylmorpholine (10 cm 3 ). The mixture was left on a roller mixer overnight.
  • Poly- ⁇ -lysine (1.57 g) was dissolved in water (25 cm 3 ) and added to the DMF damp silica particles. N-methylmorpholine (0.44 cm 3 ) was added and the mixture rolled overnight.
  • the particles were washed thoroughly with water, MeOH and DMF. Palmitic acid (1.2 g), N-hydroxysuccinimide (0.52 g) and DIC (1.1 cm 3 ) were dissolved in DMF (50 cm 3 ) and added to the DMF damp silica particles. N-methylmorpholine (0.74 cm 3 ) was added and the mixture rolled overnight. The palmitic acid coupling was repeated and the particles washed thoroughly with DMF, water and MeOH before drying in air.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
US14/112,731 2011-04-20 2012-04-20 Cross-linked poly-e-lysine particles Pending US20140154737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1106742.8 2011-04-20
GB201106742A GB201106742D0 (en) 2011-04-20 2011-04-20 Cross-linked poly-e-lysine
PCT/EP2012/057264 WO2012143508A1 (en) 2011-04-20 2012-04-20 Cross-linked poly-e-lysine particles

Publications (1)

Publication Number Publication Date
US20140154737A1 true US20140154737A1 (en) 2014-06-05

Family

ID=44147334

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/112,742 Active 2033-09-13 US9938378B2 (en) 2011-04-20 2012-04-20 Cross-linked poly-E-lysine non-particulate support
US14/112,731 Pending US20140154737A1 (en) 2011-04-20 2012-04-20 Cross-linked poly-e-lysine particles
US15/922,281 Active US10266652B2 (en) 2011-04-20 2018-03-15 Cross-linked poly-E-lysine non-particulate support

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/112,742 Active 2033-09-13 US9938378B2 (en) 2011-04-20 2012-04-20 Cross-linked poly-E-lysine non-particulate support

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/922,281 Active US10266652B2 (en) 2011-04-20 2018-03-15 Cross-linked poly-E-lysine non-particulate support

Country Status (14)

Country Link
US (3) US9938378B2 (ja)
EP (2) EP2699620B1 (ja)
JP (2) JP6262645B2 (ja)
KR (2) KR101953865B1 (ja)
CN (2) CN103619911B (ja)
AU (1) AU2012244686B2 (ja)
CA (2) CA2833589C (ja)
DK (2) DK2699620T3 (ja)
ES (2) ES2673515T3 (ja)
GB (3) GB201106742D0 (ja)
HU (2) HUE038184T2 (ja)
PT (2) PT2699619T (ja)
WO (2) WO2012143508A1 (ja)
ZA (2) ZA201307921B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165584A1 (en) * 2017-03-10 2018-09-13 University Of Florida Research Foundation Microgel particles for use in 3d printing and 3d cell growth medium and related compositions, systems, and methods
WO2021067952A1 (en) * 2019-10-04 2021-04-08 The University Of Chicago Targeted nanomedicine for treating vascular disorders

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106742D0 (en) * 2011-04-20 2011-06-01 Spheritech Ltd Cross-linked poly-e-lysine
US9724434B2 (en) 2012-03-13 2017-08-08 National University Corporation Okayama University Lysine oligomer derivative and cartilage tissue marker made thereof
GB201503566D0 (en) * 2015-03-03 2015-04-15 Spheritech Ltd Microparticles
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
GB201615050D0 (en) 2016-09-05 2016-10-19 Spheritech Ltd Microparticles
GB201615047D0 (en) * 2016-09-05 2016-10-19 Spheritech Ltd Microparticle composition and use thereof
CN106784869B (zh) * 2017-02-14 2019-09-27 安徽正熹标王新能源有限公司 一种燃料电池
JP6624746B2 (ja) * 2018-03-06 2019-12-25 国立大学法人北陸先端科学技術大学院大学 凍結による細胞内分子導入法
CN110804175B (zh) * 2019-11-08 2021-05-14 中国科学院理化技术研究所 一种交替结构抗菌聚氨基酸衍生物或共聚物及其制备方法
JPWO2022107876A1 (ja) * 2020-11-20 2022-05-27
CN114350590B (zh) * 2021-12-24 2024-06-25 大连大学 一种离子响应微胶囊及其制备方法与应用
GB202404078D0 (en) 2024-03-21 2024-05-08 Spheritech Ltd Aqueus-phase synthesis method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593658A (en) * 1992-09-04 1997-01-14 The General Hospital Corporation Medical compositions
US20080292671A1 (en) * 2005-09-09 2008-11-27 Aesculap Ag & Co. Kg Antimicrobial Medicotechnical Product, Process for its Preparation and Use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205864A (ja) 1985-03-09 1986-09-12 Meidensha Electric Mfg Co Ltd 免疫学的固相測定試薬とその調製法
JPH01126557A (ja) 1987-11-11 1989-05-18 Meidensha Corp 免疫測定用試薬
AU628988B2 (en) * 1989-05-04 1992-09-24 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors and complexes therefor
ATE177321T1 (de) 1989-12-11 1999-03-15 Immunomedics Inc Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
DK132892D0 (da) 1992-10-30 1992-10-30 Novo Nordisk As Proteiner
EP0754065A1 (en) 1994-04-04 1997-01-22 Collagen Corporation Cell-gels
JP3492951B2 (ja) * 1994-05-13 2004-02-03 株式会社クラレ 医療用高分子ゲル
JP4606524B2 (ja) * 1997-11-19 2011-01-05 チッソ株式会社 ポリリジン、及びポリリジンの製造方法、及びポリリジン組成物、及びエンドトキシンを除去する医薬品の生産方法
US6660301B1 (en) 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
JP2001126557A (ja) 1999-10-27 2001-05-11 Sumitomo Wiring Syst Ltd ワイヤハーネスの製造方法およびワイヤハーネス
JP2001128659A (ja) 1999-11-09 2001-05-15 Chisso Corp 細胞培養用粒状マイクロキャリア
JP2003033651A (ja) * 2001-07-24 2003-02-04 Chisso Corp 経口リン吸着剤及びそれを含む食品
JP2003171464A (ja) * 2001-12-06 2003-06-20 Chisso Corp ポリリジン及びその製造方法
JP2003176353A (ja) * 2001-12-13 2003-06-24 Chisso Corp ポリリジン及びその製造方法
JP4469145B2 (ja) * 2003-08-06 2010-05-26 チッソ株式会社 多糖架橋体及びその製造法。
US7834065B2 (en) 2005-01-31 2010-11-16 Bmg Incorporated Medical-use two part reactive adhesive and medical-use resin having self-degradation property
JP2006307004A (ja) * 2005-04-28 2006-11-09 Osaka Univ ポリアミノ酸を構成成分とするハイドロゲル
JP5219030B2 (ja) * 2005-11-24 2013-06-26 満 明石 刺激応答性分解ゲル
CN1850301A (zh) 2006-03-03 2006-10-25 清华大学 一种中枢神经修复用水凝胶材料及其制备方法
GB0614727D0 (en) 2006-07-25 2006-09-06 Chromatide Ltd Solid support
DE102007012253A1 (de) * 2007-03-09 2008-09-11 Aesculap Ag & Co. Kg Antimikrobielles medizintechnisches Produkt, Verfahren zu seiner Herstellung und Verwendung
WO2008149473A1 (ja) * 2007-06-07 2008-12-11 National University Corporation Kanazawa University 心筋パッド
EP2210917A1 (en) * 2007-11-01 2010-07-28 Osaka City University -1,3-glucan-derived polyaldehyde/polyamine hydrogel
EP2277547A1 (de) 2009-07-20 2011-01-26 Merck Patent GmbH Epsilon-Polylysin-Konjugate und deren Verwendung
GB2473814B (en) 2009-09-16 2014-06-11 Spheritech Ltd Hollow particulate support
GB201106742D0 (en) * 2011-04-20 2011-06-01 Spheritech Ltd Cross-linked poly-e-lysine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593658A (en) * 1992-09-04 1997-01-14 The General Hospital Corporation Medical compositions
US20080292671A1 (en) * 2005-09-09 2008-11-27 Aesculap Ag & Co. Kg Antimicrobial Medicotechnical Product, Process for its Preparation and Use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chem Europe. Dicarboxylic acids. pages 1-2. *
Oh et al. (Characteristics of an Immobilized Form of Transglutaminase: A Possible Increase in Substrate Specificity by Selective Interaction with a Protein Spacer. J. Agric. Food Chem. 1993, 41, 1337-1342) *
Russo (Reductive Glutaraldehydration of Amine Groups for Identification of Protein N-termini. J Proteome Red. 2008; 7(9):4178-4182). *
Uptima (Carbodiimides (EDAC, DCC, DIC) 2022. Pages 1-5). *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165584A1 (en) * 2017-03-10 2018-09-13 University Of Florida Research Foundation Microgel particles for use in 3d printing and 3d cell growth medium and related compositions, systems, and methods
WO2021067952A1 (en) * 2019-10-04 2021-04-08 The University Of Chicago Targeted nanomedicine for treating vascular disorders

Also Published As

Publication number Publication date
US9938378B2 (en) 2018-04-10
AU2012244686A1 (en) 2013-11-07
GB2504641A (en) 2014-02-05
GB2504439B (en) 2020-01-01
DK2699619T3 (en) 2018-03-19
KR101953865B1 (ko) 2019-03-04
HUE036430T2 (hu) 2018-07-30
GB201320463D0 (en) 2014-01-01
CN103619911B (zh) 2017-01-18
EP2699619A1 (en) 2014-02-26
HUE038184T2 (hu) 2018-10-29
JP6262645B2 (ja) 2018-01-17
CA2833695A1 (en) 2012-10-26
WO2013041250A1 (en) 2013-03-28
KR20140038417A (ko) 2014-03-28
DK2699620T3 (en) 2018-06-18
GB2504439A (en) 2014-01-29
PT2699619T (pt) 2018-03-20
EP2699619B1 (en) 2017-12-13
JP2014517855A (ja) 2014-07-24
CA2833695C (en) 2019-07-09
PT2699620T (pt) 2018-06-18
CA2833589A1 (en) 2013-03-28
AU2012244686B2 (en) 2016-05-12
CA2833589C (en) 2020-03-24
KR101976151B1 (ko) 2019-05-07
ZA201307922B (en) 2015-01-28
EP2699620B1 (en) 2018-03-21
GB201320466D0 (en) 2014-01-01
GB201106742D0 (en) 2011-06-01
GB2504641B (en) 2018-09-05
AU2012311912A1 (en) 2013-11-07
US20190023844A1 (en) 2019-01-24
US10266652B2 (en) 2019-04-23
KR20140047042A (ko) 2014-04-21
EP2699620A1 (en) 2014-02-26
CN103619911A (zh) 2014-03-05
CN103597011A (zh) 2014-02-19
WO2012143508A1 (en) 2012-10-26
ES2662902T3 (es) 2018-04-10
JP2014513737A (ja) 2014-06-05
JP6240062B2 (ja) 2017-11-29
ZA201307921B (en) 2015-01-28
US20140142198A1 (en) 2014-05-22
ES2673515T3 (es) 2018-06-22
CN103597011B (zh) 2017-10-03

Similar Documents

Publication Publication Date Title
US20140154737A1 (en) Cross-linked poly-e-lysine particles
JP5789261B2 (ja) 中空微粒子体
WO2011025445A1 (en) Method for cell expansion
GB2562004B (en) Cross-linked poly-e-lysine particles
CN106701729B (zh) 一种以多肽修饰的氨基树脂为载体的固定化酶及制备方法
AU2012311912B2 (en) Cross-linked poly-e-lysine non-particulate support
CN112126638B (zh) 一种脂肪酶固载树脂及其制备方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: SPHERITECH LTD, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WELLINGS, DONALD;REEL/FRAME:032027/0074

Effective date: 20131120

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED